Wed, Nov 13, 10:30 PM (236 days ago)
Aytu BioPharma, Inc. (AYTU) reported its Q1 FY2025 results, revealing a net income of $1.5 million, a significant improvement from a loss of $8.1 million in Q1 FY2024. Revenue decreased by 7% to $16.6 million, primarily due to a drop in the Pediatric Portfolio, offset by a $3.3 million adjustment from vendor negotiations that positively impacted the ADHD Portfolio. Gross profit margin slightly declined to 72%. Operating expenses fell 7% to $12.9 million, driven by reduced selling, general, and administrative costs. The company incurred $0.8 million in restructuring costs related to its Consumer Health business divestiture. Interest expenses decreased to $1 million, aided by favorable loan terms from the new Eclipse Term Loan, which replaced a higher-interest loan. The company maintains liquidity through a $14.5 million revolving credit facility and a $13 million term loan, both maturing in June 2028. Looking ahead, Aytu faces potential market competition with the recent Paragraph IV certification notice from Granules Pharmaceuticals regarding a generic version of Adzenys. The company continues to focus on its ADHD and Pediatric product portfolios while navigating inflationary pressures and supply chain challenges.